Ishida Cecilia, Zubair Muhammad, Gupta Vikas
UNAM
Pakistan Kidney & Liver Institute and Research Centre - PKLI
Molecular genetics testing is fundamental in evaluating inherited disorders, somatic or acquired diseases with genetic associations, and pharmacogenetic responses. Genotyping can provide valuable disease diagnosis, prognosis, and progression indicators, guide treatment selection and response, and identify gene-specific therapeutic targets. Human genetic material primarily consists of double-stranded, helical DNA. This molecule has a backbone composed of alternating sugar (deoxyribose) and phosphate groups, with hydrogen bonds linking nitrogenous base pairs. Specifically, adenine (purine) pairs with thymine (pyrimidine), while guanine (purine) pairs with cytosine (pyrimidine), forming the complementary base pairs within the DNA double helix. DNA in human cells is wrapped around histone proteins and packaged into nucleosome units, compacted further to form chromosomes. Somatic cells normally have 23 chromosome pairs, with 1 pair comprised of the sex chromosomes X and Y. Each chromosome has DNA with a terminal stretch of short repeats called “telomeres” and additional repeats in the centromere region. Humans have 2 sets of 23 chromosomes, one derived from the mother’s egg and the other from the father's sperm. Therefore, each egg and sperm is a single or haploid set of 23 chromosomes. Combining the 2 creates a diploid set of human DNA, allowing each individual to possess 2 different sequences, genes, and alleles on each chromosome. Homologous recombination during meiosis generates unique allele combinations in gametes, leading to genetic diversity among offspring in the human population. The complete decoding of the human genome sequence and the development of powerful identification and cloning methods for genes linked to inherited diseases have transformed the practice of molecular genetics and molecular pathology. Advanced molecular analysis methods can now determine presymptomatic individuals' illness risk, detect asymptomatic recessive trait carriers, and prenatally diagnose conditions not yet evident in pregnancy. Molecular genetics techniques are often the only approaches to these puzzles. Thus, genetic tests are powerful tools for diagnosis, genetic consultation, and prevention of heritable diseases. Many genetic tests can analyze gene, chromosome, and protein alterations. A clinician often considers several factors when selecting the appropriate test, including suspected conditions and their possible genetic variations. A broad genetic test is employed when a diagnosis is uncertain, while a targeted test is preferred for suspected specific conditions. Molecular tests look for changes in 1 or more genes. These tests analyze the sequence of DNA building blocks (nucleotides) in an individual's genetic code, a process known as DNA sequencing, which can vary in scope. The targeted single variant test identifies a specific variant in a single gene known to cause a disorder, eg, the gene variant causing β-globin abnormalities that give rise to sickle cell disease. This test assesses the family members of an individual with the known variant to ascertain if they have the familial condition. Single-gene tests examine genetic alterations in 1 gene to confirm or rule out a specific diagnosis, notably when many variants in the gene can cause the suspected condition. Gene panel tests look for variants in multiple genes to pinpoint a diagnosis when a person has symptoms that may fit various conditions or when many gene variants can cause the suspected condition. Whole-exome sequencing or whole-genome sequencing tests analyze the bulk of an individual's DNA to find genetic variations. This approach is useful when a single-gene or panel testing has not provided a diagnosis or when the suspected condition or genetic cause is unclear. This sequencing method is often more cost- and time-effective than performing multiple single gene or panel tests. Chromosomal tests analyze whole chromosomes or long DNA lengths to identify significant alterations, including extra or missing chromosome copies (trisomy or monosomy), large chromosomal segment duplications or deletions, and segment rearrangements (translocations) (see . Trisomy 21 on G-Banded Chromosomal Studies). Chromosomal tests are employed when specific genetic conditions linked to chromosomal changes are suspected. For instance, Williams syndrome results from deleting a chromosome 7 segment. Gene expression tests assess gene activation status in cells, indicating whether genes are active or inactive, with activated genes producing mRNA molecules that serve as templates for protein synthesis. The mRNA produced helps determine which genes are highly active. Too much activity (overexpression) or too little activity (underexpression) of specific genes may suggest particular genetic disorders, including various cancer types. Biochemical tests assess protein or enzyme levels and activity rather than directly analyzing DNA. Abnormalities in these substances may indicate DNA changes underlying a genetic disorder. Heritable mutations are detectable in all nucleated cells and are thus considered germline or constitutional genetic changes. Somatic genetic changes are characteristic of acquired or sporadic diseases like cancer. Both scenarios are investigated using similar molecular biology methods to detect DNA and RNA variations, although the interpretation and utility of the laboratory results often differ significantly. Fluorescent in situ hybridization (FISH), chromosomal microarray analysis (CMA), and cytogenetic analysis (karyotyping) can be used to detect gross mutations like whole- and large-scale gene deletions, duplications, or rearrangements. Conventional karyotyping identifies rearrangements over 5 DNA megabases. FISH has a resolution of 100 kilobases to 1 megabase. Minor alterations, such as single-base substitutions, insertions, and deletions, are detectable with single-strand conformation polymorphism (SSCP) and sequence analysis through next-generation sequencing (NGS). NGS uses genomic DNA (gDNA) or complementary DNA (cDNA) and has 3 modalities: whole genomic DNA, targeted, and exome sequencing. Denaturing high-performance liquid chromatography (DHPLC) can detect small deletions and duplications. Multiplex ligation-dependent probe amplification (MLPA) extends the range of deletions and duplications detected, bridging the gap between FISH or cytogenetic analysis and HPLC. MLPA is particularly useful in identifying complete or single and multiexon deletions or duplications.
分子遗传学检测在评估遗传性疾病、具有遗传关联的体细胞或后天性疾病以及药物遗传学反应方面至关重要。基因分型能够提供有价值的疾病诊断、预后和进展指标,指导治疗选择及反应,并确定基因特异性治疗靶点。人类遗传物质主要由双链螺旋DNA组成。该分子具有由交替的糖(脱氧核糖)和磷酸基团构成的骨架,氢键连接着碱基对。具体而言,腺嘌呤(嘌呤)与胸腺嘧啶(嘧啶)配对,鸟嘌呤(嘌呤)与胞嘧啶(嘧啶)配对,在DNA双螺旋结构中形成互补碱基对。人类细胞中的DNA缠绕在组蛋白周围,并包装成核小体单元,进一步压缩形成染色体。体细胞通常有23对染色体,其中1对由性染色体X和Y组成。每条染色体的DNA都有一段末端短重复序列,称为“端粒”,在着丝粒区域还有额外的重复序列。人类有2套23条染色体,一套来自母亲的卵子,另一套来自父亲的精子。因此,每个卵子和精子都是一套单倍体的23条染色体。两者结合形成一套二倍体的人类DNA,使得每个人在每条染色体上都拥有2种不同的序列、基因和等位基因。减数分裂期间的同源重组在配子中产生独特的等位基因组合,导致人类群体后代的遗传多样性。人类基因组序列的完全解码以及与遗传性疾病相关基因的强大鉴定和克隆方法的发展,改变了分子遗传学和分子病理学的实践。先进的分子分析方法现在可以确定症状前个体的患病风险,检测无症状隐性性状携带者,并在产前诊断出孕期尚未显现的病症。分子遗传学技术往往是解决这些难题的唯一方法。因此,基因检测是诊断、遗传咨询和预防遗传性疾病的有力工具。许多基因检测可以分析基因、染色体和蛋白质的改变。临床医生在选择合适的检测时通常会考虑几个因素,包括疑似病症及其可能的基因变异。当诊断不确定时,采用广泛的基因检测;而对于疑似特定病症,则首选靶向检测。分子检测寻找一个或多个基因的变化。这些检测分析个体遗传密码中DNA构建块(核苷酸)的序列,这一过程称为DNA测序,其范围可能有所不同。靶向单变异检测可识别已知导致疾病的单个基因中的特定变异,例如导致β-珠蛋白异常从而引发镰状细胞病的基因变异。该检测评估携带已知变异个体的家庭成员,以确定他们是否患有家族性疾病。单基因检测检查单个基因中的遗传改变,以确认或排除特定诊断,特别是当基因中的许多变异都可能导致疑似病症时。基因panel检测寻找多个基因中的变异,以便在一个人出现可能符合多种病症的症状时,或者当许多基因变异都可能导致疑似病症时,精确做出诊断。全外显子测序或全基因组测序检测分析个体的大部分DNA以寻找遗传变异。当单基因或panel检测未能提供诊断,或者疑似病症或遗传原因不明确时,这种方法很有用。这种测序方法通常比进行多个单基因或panel检测更具成本效益和时间效益。染色体检测分析整条染色体或长DNA片段,以识别重大改变,包括染色体拷贝数的增加或减少(三体或单体)、大的染色体片段重复或缺失以及片段重排(易位)(见G带染色体研究中的21三体)。当怀疑存在与染色体变化相关的特定遗传病症时,会采用染色体检测。例如,威廉姆斯综合征是由于7号染色体片段缺失所致。基因表达检测评估细胞中的基因激活状态,表明基因是活跃还是不活跃,被激活的基因会产生作为蛋白质合成模板的mRNA分子。产生的mRNA有助于确定哪些基因高度活跃。特定基因的活性过高(过表达)或过低(低表达)可能提示特定的遗传病症,包括各种癌症类型。生化检测评估蛋白质或酶的水平和活性,而不是直接分析DNA。这些物质的异常可能表明遗传病症背后的DNA变化。可在所有有核细胞中检测到可遗传突变,因此被视为种系或体质性遗传变化。体细胞遗传变化是癌症等后天性或散发性疾病的特征。虽然实验室结果的解释和用途通常有很大差异,但两种情况都使用类似的分子生物学方法来检测DNA和RNA变异。荧光原位杂交(FISH)、染色体微阵列分析(CMA)和细胞遗传学分析(核型分析)可用于检测大片段突变,如全基因组和大规模基因缺失、重复或重排。传统核型分析可识别超过5兆碱基的重排。FISH的分辨率为100千碱基至1兆碱基。单链构象多态性(SSCP)和通过下一代测序(NGS)进行的序列分析可检测微小改变,如单碱基替换、插入和缺失。NGS使用基因组DNA(gDNA)或互补DNA(cDNA),有3种模式:全基因组DNA、靶向和外显子测序。变性高效液相色谱(DHPLC)可检测小的缺失和重复。多重连接依赖探针扩增(MLPA)扩展了可检测的缺失和重复范围,弥合了FISH或细胞遗传学分析与HPLC之间的差距。MLPA在识别完整或单个及多个外显子的缺失或重复方面特别有用。